Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 301 to 315 of 1425 results for primary care

  1. Social anxiety disorder: recognition, assessment and treatment (CG159)

    This guideline covers recognising, assessing and treating social anxiety disorder (also known as ‘social phobia’) in children and young people (from school age to 17 years) and adults (aged 18 years and older). It aims to improve symptoms, educational, occupational and social functioning, and quality of life in people with social anxiety disorder.

  2. Other specialist management:- What specialist management is effective for people whose symptoms do not respond to PPIs despite optimum primary care, or for people whose symptoms return after surgery?

    effective for people whose symptoms do not respond to PPIs despite optimum primary care, or for people whose symptoms return after...

  3. Get involved

    Tell us what matters to you, your organisation or your community.

  4. Get involved

    Tell us what matters to you, your organisation or your community.

  5. Fetal alcohol spectrum disorder (QS204)

    This quality standard covers assessing and diagnosing fetal alcohol spectrum disorder (FASD) in children and young people. It also covers support during pregnancy to prevent FASD. It describes high-quality care in priority areas for improvement.

  6. Major trauma: assessment and initial management (NG39)

    This guideline covers the rapid identification and early management of major trauma in pre-hospital and hospital settings, including ambulance services, emergency departments, major trauma centres and trauma units. It aims to reduce deaths and disabilities in people with serious injuries by improving the quality of their immediate care. It does not cover care for people with burns.

  7. Nirogacestat for treating desmoid tumours [ID6453]

    In development Reference number: GID-TA11559 Expected publication date:  10 June 2026

  8. Vaccine uptake in the general population (NG218)

    This guideline aims to increase the uptake of all vaccines provided on the NHS routine UK immunisation schedule by everyone who is eligible. It supports the aims of the NHS Long Term Plan , which includes actions to improve immunisation coverage by GPs (including the changes to vaccinations and immunisations detailed in the 2021/2022 and 2022/23 GP contracts ) and support a narrowing of health inequalities.

  9. 12 SQ-HDM SLIT for treating allergic rhinitis and allergic asthma caused by house dust mites (TA1045)

    Evidence-based recommendations on 12 standard quality house dust mite sublingual lyophilisate (SQ-HDM SLIT; Acarizax) for treating allergic rhinitis and allergic asthma caused by house dust mites.

  10. Technology appraisal committee C members

    Biographies and registered interests for members of the Technology Appraisal Committee C

  11. Technology appraisal committee C members

    Biographies and registered interests for members of the Technology Appraisal Committee C

  12. Non-alcoholic fatty liver disease (NAFLD): assessment and management (NG49)

    This guideline covers how to identify the adults, young people and children with non-alcoholic fatty liver disease (NAFLD) who have advanced liver fibrosis and are most at risk of further complications. It outlines the lifestyle changes and pharmacological treatments that can manage NAFLD and advanced liver fibrosis.

  13. Rivaroxaban for the prevention of stroke and systemic embolism in people with atrial fibrillation (TA256)

    Evidence-based recommendations on rivaroxaban (Xarelto) for preventing stroke and systemic embolism in adults with non-valvular atrial fibrillation.

  14. Bipolar, schizophrenia and other psychoses: care planning (IND143)

    This indicator covers the percentage of patients with schizophrenia, bipolar affective disorder and other psychoses who have a comprehensive care plan documented in the record, in the preceding 12 months, agreed between individuals, their family and/or carers as applicable. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM108